2023 International Bladder Cancer Network

Viewing 1-18 of 18 articles

IBCN 2023: Proteogenomic Characterization of Chemotherapy Response in Muscle Invasive Bladder Cancer

IBCN 2023: Initial Results From The Prospective Randomized UroFollow Trial Comparing Markerguided vs. Cystoscopy-Based Standard Follow-Up In Patients With Low/Intermediate Risk Bladder Cancer

IBCN 2023: Urinary Comprehensive Genomic Profiling Predicts Urothelial Cancer Up To 12 Years Ahead Of Clinical Diagnosis: An Expanded Analysis Of The Golestan Cohort Study

IBCN 2023: A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy in Select Muscle-Invasive Bladder Cancer Patients

IBCN 2023: Molecular Signatures Predict GEMDOCE Responses for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

IBCN 2023: Simulating The Effects of Molecular Urine Markers In Follow-Up Of Patients With High Risk Non-Muscle Invasive Bladder Cancer

IBCN 2023: Added Value of ctDNA Testing For Identifying FGFR3 Alterations In Metastatic Urothelial Cancer Eligible For Erdafitinib Treatment

IBCN 2023: Gene Expression-Based Classification of Urothelial Carcinoma For Research And Clinical Applications

IBCN 2023: Alignment Of Molecular Subtypes Across Multiple Bladder Cancer Subtyping Classifiers

IBCN 2023: Meta-Analysis of GWAS Data from Diverse Populations for Bladder Cancer (mapBC) Collaboration: Initial Findings

IBCN 2023: Exploring the Impact of Microbiome in the Response of Combined Radiation with Immune Checkpoint Blockade in Muscle Invasive Bladder Cancer

IBCN 2023: Patient-Derived Organoids Identify Tailored Therapeutic Options and Determinants of Plasticity in Sarcomatoid Urothelial Bladder Cancer

IBCN 2023: Field Cancerization Impacts Tumor Development, T-Cell Exhaustion and Clinical Outcomes in Bladder Cancer

IBCN 2023: Evaluation of Molecular Residual Disease by Urinary Comprehensive Genomic Profiling in the SWOG S1605 Phase II Study of Atezolizumab in Patients with BCG Unresponsive NMIBC

IBCN 2023: An Holistic and Intergrated Approach for Investigating the Bacterial Microbiome, Gene Expression Profile and Immune Cell Profile in the Non-Muscle Invasive Bladder Cancer Tumour Microenvironment

IBCN 2023: SURE-01: Interim Results of a Phase 2 Study of Neoadjuvant Sacituzumab Govitecan, Followed by Radical Cystectomy, for Patients with Muscle-Invasive Bladder Cancer

IBCN 2023: Transurethral Resections of Bladder Tumor Quality Criteria and Early Recurrence Rate: Preliminary Data from the International RESECT Study

IBCN 2023: Long Term Recurrence Risk, Metastatic Potential, and Length of Surveillance of Low Grade Non-Muscle Invasive Bladder Cancer